Quick Answer
Pelthos Therapeutics Inc. reported Stockholders Equity of $38.88 million for fiscal year 2025.
Pelthos Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $38.88M | +1532.6% |
| 2024 | -$2.71M | +57.9% |
| 2023 | -$6.45M | -73.9% |
| 2022 | -$3.71M | -0.7% |
| 2021 | -$3.68M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.25M | +4179.3% | +997.0% |
| June 30, 2025 | -$6.49M | -3429.3% | -54.8% |
| March 31, 2025 | -$4.20M | -471.3% | -54.6% |
| December 31, 2024 | -$2.71M | +57.9% | -90.1% |
| September 30, 2024 | -$1.43M | +75.8% | -676.1% |
| June 30, 2024 | -$184.0K | +96.2% | -116.3% |
| March 31, 2024 | $1.13M | +125.4% | +117.5% |
| December 31, 2023 | -$6.45M | -73.9% | -9.2% |
- Pelthos Therapeutics Inc. showed an increase of +1532.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Pelthos Therapeutics Inc.’s stockholders equity has grown by 1156.5% (from -$3.68 million to $38.88 million).
- The most recent figure is from Pelthos Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: